British pharmaceutical giant AstraZeneca has officially opened a new global research and development (R&D) centre at the BioPark Innovation Complex in Beijing’s Economic and Technological Development Zone.
This marks the company’s sixth global R&D hub and its second in China, following the first established in Shanghai. The new Beijing facility aims to harness the capital’s strong scientific ecosystem and advancements in artificial intelligence to accelerate the development of next-generation innovative medicines.
The centre will work closely with AstraZeneca’s global strategic R&D hub in Shanghai to lead drug discovery and clinical development efforts, turning cutting-edge innovations into new treatments more efficiently.
He Jing, AstraZeneca’s Senior Vice President and Head of R&D in China, said that research and development in new medicines serve as a key driver for the pharmaceutical industry. She emphasised that the company seeks to create strong synergies through collaboration with ecosystem partners, leveraging each party’s strengths to advance global health innovation.
She added that the Beijing centre would benefit from the robust R&D infrastructure, resources, and support within the Beijing Economic and Technological Development Zone, enhancing cooperation with research hospitals, universities, and biotech companies.
The zone has become a major hub for high-tech industries and the biomedical sector, hosting more than 5,000 biopharmaceutical companies, including global leaders such as Pfizer, Bayer, and Sanofi, alongside domestic players like Beijing Tide Pharmaceutical and YuCare Pharmaceutical Group.
Since early 2025, two innovative drugs and three medical devices developed within the zone have received official approval, underscoring Beijing’s growing role as a centre for medical and technological innovation.
Follow the latest news on Google News
